Stock Taper
SCREENER COMPARE ANY 2 STOCKS
INKT
MINK THERAPEUTICS, INC.
NASDAQ
$12.20
▲ UP 4.99% (0.58)

KEY STATISTICS

Market Cap$60.78 M
52w High$16.98
52w Low$8.48
Dividend Yield—
Frequency—
P/E-5.17
Volume11.78K
Shares Out.4.98M

COMPANY

LEADERSHIP

Jennifer S. Buell
CHIEF EXECUTIVE
Jennifer S. Buell

COMPENSATION 2026

Salary$448,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$5,686
Total$2,087,881

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 15, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
15

PRICE TARGET

Target High$35.00
Target Low$35.00
Target Median$35.00
Target Consensus$35.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$1.60M
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2025-01-28Reverse1:10

PRICE

$12.20 ▲ UP 4.99% (+$0.58)
OVERLAYS
$11.40$11.70$12.009:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM12.20

About MiNK Therapeutics, Inc.

https://minktherapeutics.com ↗

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf iNKT cell therapies, including AGENT-797 for myeloma, and is a subsidiary of Agenus Inc., based in New York.

INDUSTRY

Biotechnology

A PRODUCT MINK THERAPEUTICS, INC. IS KNOWN FOR

AGENT-797
AGENT-797

AGENT-797 is MiNK Therapeutics' off-the-shelf allogeneic iNKT cell therapy in clinical trials for cancers and immune diseases.

COMPETITORS

COMPETITOR
ACET COMPARE
ALLO COMPARE
FATE COMPARE
IPSC COMPARE
NKTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
12
LISTED HERE
2
RANKED BY POSITION SIZE
VTS.AX
0.00% · 53.1K
IWC
0.01% · 6.8K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
2.96%
HOLDERS
24
TOP 12 OF 24 · RANKED BY POSITION SIZE
Blackrock Inc.
87.2K sh · $82.77K
Geode Capital Management, LLC
17.3K sh · $182.67K
Longbow Finance SA
16.7K sh · $175.5K
Ubs Group AG
15.2K sh · $160.08K
Blackrock, Inc.
6.2K sh · $65.32K
Steward Partners Investment Advisory, LLC
2.0K sh · $21.06K
First Command Financial Services, Inc.
1.0K sh · $2.17K
First Command Bank
1.0K sh · $2.17K
Amalgamated Financial Corp.
295 sh · $1K
Annis Gardner Whiting Capital Advisors, LLC
200 sh · $2.11K
Tower Research Capital LLC (Trc)
156 sh · $1.64K
Covestor Ltd
119 sh · $1K

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Ryan Barbara
Sale · 500 shares
2026-06-04
★
DIRECTOR
Ryan Barbara
Sale · 1.0K shares
2026-06-04
★
DIRECTOR
WIINBERG ULF
Purchase · 1.3K shares
2026-03-02
★
DIRECTOR
WIINBERG ULF
Purchase · 1.1K shares
2026-06-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
EQ$2.31COMPARE
SPRB$51.58COMPARE
OTLK$0.65COMPARE
VTVT$33.26COMPARE
GANX$2.00COMPARE
OSTX$1.59COMPARE
NRXP$3.56COMPARE
HOWL$0.87COMPARE